Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen, Inc.

http://www.amgen.com

Latest From Amgen, Inc.

Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases

EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.

Financing Business Strategies

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.

Reimbursement Medicare

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

Medicare Reimbursement

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.

Emerging Company Profile Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Abgenix
    • Amgen Astellas BioPharma K.K.
    • Amgen K.K.
    • Avidia
    • BioVex Group
    • Catherex, Inc.
    • ChemoCentryx, Inc.
    • deCODE Genetics
    • Dezima Pharma B.V.
    • Five Prime Therapeutics, Inc.
    • Ilypsa
    • Immunex Corporation
    • KAI Pharmaceuticals
    • Kirin-Amgen Inc.
    • Laboratorio Quimico Farmaceutico Bergamo Ltd
    • Micromet, Inc. (CancerVax Corporation)
    • Nuevolution AB
    • Nuevolution A/S
    • Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
    • Saga Investments LLC
    • Tularik
UsernamePublicRestriction

Register